{"data":{"id":"10.6084/m9.figshare.3381295","type":"dois","attributes":{"doi":"10.6084/m9.figshare.3381295","prefix":"10.6084","suffix":"m9.figshare.3381295","identifiers":[],"alternateIdentifiers":[],"creators":[{"name":"Akhilesh  Gupta","affiliation":[],"nameIdentifiers":[]}],"titles":[{"title":"Method development and hydrolytic degradation study of doxofylline by rp-hplc and lc-ms/ms"}],"publisher":"figshare","container":{},"publicationYear":2016,"subjects":[{"subject":"60101 Analytical Biochemistry","subjectScheme":"FOR"},{"subject":"FOS: Biological sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Biological sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"30199 Analytical Chemistry not elsewhere classified","subjectScheme":"FOR"},{"subject":"FOS: Chemical sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Chemical sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"30101 Analytical Spectrometry","subjectScheme":"FOR"},{"subject":"30105 Instrumental Methods (excl. Immunological and Bioassay Methods)","subjectScheme":"FOR"},{"subject":"30405 Molecular Medicine","subjectScheme":"FOR"},{"subject":"FOS: Basic medicine","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Basic medicine","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"Molecular Physics"},{"subject":"30302 Nanochemistry and Supramolecular Chemistry","subjectScheme":"FOR"},{"subject":"30502 Natural Products Chemistry","subjectScheme":"FOR"},{"subject":"NMR Spectroscopy"},{"subject":"30503 Organic Chemical Synthesis","subjectScheme":"FOR"},{"subject":"Organic Chemistry"},{"subject":"30599 Organic Chemistry not elsewhere classified","subjectScheme":"FOR"},{"subject":"30106 Quality Assurance, Chemometrics, Traceability and Metrological Chemistry","subjectScheme":"FOR"},{"subject":"111002 Clinical Nursing: Primary (Preventative)","subjectScheme":"FOR"},{"subject":"FOS: Health sciences","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Health sciences","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"111003 Clinical Nursing: Secondary (Acute Care)","subjectScheme":"FOR"},{"subject":"111004 Clinical Nursing: Tertiary (Rehabilitative)","subjectScheme":"FOR"},{"subject":"111502 Clinical Pharmacology and Therapeutics","subjectScheme":"FOR"},{"subject":"FOS: Clinical medicine","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Clinical medicine","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"111503 Clinical Pharmacy and Pharmacy Practice","subjectScheme":"FOR"},{"subject":"110399 Clinical Sciences not elsewhere classified","subjectScheme":"FOR"},{"subject":"111504 Pharmaceutical Sciences","subjectScheme":"FOR"},{"subject":"111505 Pharmacogenomics","subjectScheme":"FOR"},{"subject":"FOS: Medical biotechnology","schemeUri":"http://www.oecd.org/science/inno/38235147.pdf","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"FOS: Medical biotechnology","subjectScheme":"Fields of Science and Technology (FOS)"},{"subject":"111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified","subjectScheme":"FOR"},{"subject":"110203 Respiratory Diseases","subjectScheme":"FOR"}],"contributors":[],"dates":[{"date":"2016-05-15","dateType":"Created"},{"date":"2016-05-15","dateType":"Updated"},{"date":"2016","dateType":"Issued"}],"language":null,"types":{"ris":"DATA","bibtex":"misc","citeproc":"dataset","schemaOrg":"Dataset","resourceType":"Dataset","resourceTypeGeneral":"Dataset"},"relatedIdentifiers":[],"relatedItems":[],"sizes":["496067 Bytes"],"formats":[],"version":null,"rightsList":[{"rights":"Creative Commons Attribution 4.0 International","rightsUri":"https://creativecommons.org/licenses/by/4.0/legalcode","schemeUri":"https://spdx.org/licenses/","rightsIdentifier":"cc-by-4.0","rightsIdentifierScheme":"SPDX"}],"descriptions":[{"description":"A simple, rapid and accurate RP-HPLC method was developed for the determination of doxofylline and photolyticdegradation product. The method showed a linear response for concentrations in the range of 1-200 g/ml usingacetonitrile: formic acid (90: 10); pH-3.0 as the mobile phase with detection at 274 nm and a flow rate of 1 ml/min and retention time 2.9 min. The method was statistically validated for accuracy, precision, linearity, ruggedness,robustness, forced degradation, solution stability and selectivity. Quantitative and recovery studies of the dosage form were also carried out and analyzed; the % RSD from recovery studies was found to be less than 1. Due to simplicity, rapidity and accuracy of the method, we believe that the method will be useful for routine quality control analysis. The hydrolytic degradation product as well as pathway was characterized by LC-MS/MS.RESULT AND DISCUSSION:A sensitive, selective, precise and accurate highperformance liquid chromatographic method of analysis ofdoxofylline in both as bulk drug and in formulation wasdeveloped and validated. The mobile phase consisted ofacetonitril: 0.05M formic Acid (90: 10v/v); pH-3.0. Thedetection wavelength was 274nm. This system was found to give the sharp peak for doxofylline (RT-2.9). The methodwas validated as per ICH guideline (table 1). Stabilityindicating assay method in which hydrolytic stresscondition was used for quantitative estimation ofdoxofylline in tablet formulation and identification ofhydrolytic degradation product The separation of drugfrom its degradation product were optimized by varying theratio \u0026amp;/or nature of organic modifier. Finally method wasdeveloped using same mobile phase composed ofacetonitrile: formic acid (90: 10); pH-3.0, in that both drugand degradation product showing good elution RT-2.9(Doxofylline) and RT-3.68 (Hydrolytic degradationproduct) and m/e-229 (fig 4). The hydrolytic degradationproduct and pure drug were identified by LC-MS/MS inorder to establish hydrolytic degradation pathway (fig 5 and6).\u003cbr\u003e","descriptionType":"Abstract"}],"geoLocations":[],"fundingReferences":[],"xml":"<?xml version="1.0" encoding="UTF-8"?>
<resource xmlns="http://datacite.org/schema/kernel-4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.6084/M9.FIGSHARE.3381295</identifier>
  <creators>
    <creator>
      <creatorName>Akhilesh  Gupta</creatorName>
    </creator>
  </creators>
  <titles>
    <title>Method development and hydrolytic degradation study of doxofylline by rp-hplc and lc-ms/ms</title>
  </titles>
  <descriptions>
    <description descriptionType="Abstract">&lt;div&gt;A simple, rapid and accurate RP-HPLC method was developed for the determination of doxofylline and photolytic&lt;/div&gt;&lt;div&gt;degradation product. The method showed a linear response for concentrations in the range of 1-200  g/ml using&lt;/div&gt;&lt;div&gt;acetonitrile: formic acid (90: 10); pH-3.0 as the mobile phase with detection at 274 nm and a flow rate of 1 ml/min and retention time 2.9 min. The method was statistically validated for accuracy, precision, linearity, ruggedness,&lt;/div&gt;&lt;div&gt;robustness, forced degradation, solution stability and selectivity. Quantitative and recovery studies of the dosage form were also carried out and analyzed; the % RSD from recovery studies was found to be less than 1. Due to simplicity, rapidity and accuracy of the method, we believe that the method will be useful for routine quality control analysis. The hydrolytic degradation product as well as pathway was characterized by LC-MS/MS.&lt;/div&gt;&lt;div&gt;&lt;div&gt;RESULT AND DISCUSSION:&lt;/div&gt;&lt;div&gt;A sensitive, selective, precise and accurate high&lt;/div&gt;&lt;div&gt;performance liquid chromatographic method of analysis of&lt;/div&gt;&lt;div&gt;doxofylline in both as bulk drug and in formulation was&lt;/div&gt;&lt;div&gt;developed and validated. The mobile phase consisted of&lt;/div&gt;&lt;div&gt;acetonitril: 0.05M formic Acid (90: 10v/v); pH-3.0. The&lt;/div&gt;&lt;div&gt;detection wavelength was 274nm. This system was found to give the sharp peak for doxofylline (RT-2.9). The method&lt;/div&gt;&lt;div&gt;was validated as per ICH guideline (table 1). Stability&lt;/div&gt;&lt;div&gt;indicating assay method in which hydrolytic stress&lt;/div&gt;&lt;div&gt;condition was used for quantitative estimation of&lt;/div&gt;&lt;div&gt;doxofylline in tablet formulation and identification of&lt;/div&gt;&lt;div&gt;hydrolytic degradation product The separation of drug&lt;/div&gt;&lt;div&gt;from its degradation product were optimized by varying the&lt;/div&gt;&lt;div&gt;ratio &amp;/or nature of organic modifier. Finally method was&lt;/div&gt;&lt;div&gt;developed using same mobile phase composed of&lt;/div&gt;&lt;div&gt;acetonitrile: formic acid (90: 10); pH-3.0, in that both drug&lt;/div&gt;&lt;div&gt;and degradation product showing good elution RT-2.9&lt;/div&gt;&lt;div&gt;(Doxofylline) and RT-3.68 (Hydrolytic degradation&lt;/div&gt;&lt;div&gt;product) and m/e-229 (fig 4). The hydrolytic degradation&lt;/div&gt;&lt;div&gt;product and pure drug were identified by LC-MS/MS in&lt;/div&gt;&lt;div&gt;order to establish hydrolytic degradation pathway (fig 5 and&lt;/div&gt;&lt;div&gt;6).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;br&gt;&lt;/div&gt;</description>
  </descriptions>
  <subjects>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">60101 Analytical Biochemistry</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30199 Analytical Chemistry not elsewhere classified</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30101 Analytical Spectrometry</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30105 Instrumental Methods (excl. Immunological and Bioassay Methods)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30405 Molecular Medicine</subject>
    <subject>Molecular Physics</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30302 Nanochemistry and Supramolecular Chemistry</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30502 Natural Products Chemistry</subject>
    <subject>NMR Spectroscopy</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30503 Organic Chemical Synthesis</subject>
    <subject>Organic Chemistry</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30599 Organic Chemistry not elsewhere classified</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">30106 Quality Assurance, Chemometrics, Traceability and Metrological Chemistry</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111002 Clinical Nursing: Primary (Preventative)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111003 Clinical Nursing: Secondary (Acute Care)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111004 Clinical Nursing: Tertiary (Rehabilitative)</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111502 Clinical Pharmacology and Therapeutics</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111503 Clinical Pharmacy and Pharmacy Practice</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110399 Clinical Sciences not elsewhere classified</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111504 Pharmaceutical Sciences</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111505 Pharmacogenomics</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified</subject>
    <subject schemeURI="http://www.abs.gov.au/ausstats/abs@.nsf/0/6BB427AB9696C225CA2574180004463E" subjectScheme="FOR">110203 Respiratory Diseases</subject>
  </subjects>
  <publisher>figshare</publisher>
  <publicationYear>2016</publicationYear>
  <dates>
    <date dateType="Created">2016-05-15</date>
    <date dateType="Updated">2016-05-15</date>
  </dates>
  <resourceType resourceTypeGeneral="Dataset">Dataset</resourceType>
  <sizes>
    <size>496067 Bytes</size>
  </sizes>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</rights>
  </rightsList>
</resource>","url":"https://figshare.com/articles/dataset/Method_development_and_hydrolytic_degradation_study_of_doxofylline_by_rp-hplc_and_lc-ms_ms/3381295","contentUrl":null,"metadataVersion":1,"schemaVersion":"http://datacite.org/schema/kernel-4","source":"mds","isActive":true,"state":"findable","reason":null,"viewCount":0,"viewsOverTime":[],"downloadCount":0,"downloadsOverTime":[],"referenceCount":0,"citationCount":0,"citationsOverTime":[],"partCount":0,"partOfCount":0,"versionCount":0,"versionOfCount":0,"created":"2016-05-15T06:27:05.000Z","registered":"2016-05-15T06:27:06.000Z","published":"2016","updated":"2020-09-04T11:03:34.000Z"},"relationships":{"client":{"data":{"id":"figshare.ars","type":"clients"}},"provider":{"data":{"id":"otjm","type":"providers"}},"media":{"data":{"id":"10.6084/m9.figshare.3381295","type":"media"}},"references":{"data":[]},"citations":{"data":[]},"parts":{"data":[]},"partOf":{"data":[]},"versions":{"data":[]},"versionOf":{"data":[]}}}}